Our platform
We are currently developing a platform of Pannexin 1 channel blockers optimized and specific for different therapeutic areas and indications, like CNS, cancer, inflammatory, cardiovascular, pulmonary etc.
Our portfolio
Currently we are working on our first target indication, which is chronic pain / opioid addiction, but we will select during 2022 additional three potential target indications.
Partner with us
Pannexin 1 channel blockers have a potential in many therapeutic areas, we are open to partner therapeutic areas or indications.